ALPAPharmaceuticals
Alpa Laboratories Ltd — Profit & Loss Statement
₹46.46
-9.93%
Alpa Laboratories Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 0.75 Cr | 2.32 Cr | — |
| Tax Rate For Calcs | 0.24 | 0.19 | 0.28 | 0.28 | — |
| Normalized EBITDA | 28.10 Cr | 23.00 Cr | 14.62 Cr | 13.03 Cr | — |
| Total Unusual Items | 0.00 | 0.00 | 2.68 Cr | 8.30 Cr | — |
| Total Unusual Items Excluding Goodwill | 0.00 | 0.00 | 2.68 Cr | 8.30 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 19.50 Cr | 16.78 Cr | 12.58 Cr | 14.09 Cr | — |
| Reconciled Depreciation | 2.20 Cr | 1.95 Cr | 1.33 Cr | 1.66 Cr | — |
| Reconciled Cost Of Revenue | 76.47 Cr | 74.60 Cr | 61.50 Cr | 76.09 Cr | — |
| EBITDA | 28.10 Cr | 23.00 Cr | 17.30 Cr | 21.33 Cr | — |
| EBIT | 25.90 Cr | 21.04 Cr | 15.97 Cr | 19.67 Cr | — |
| Net Interest Income | -0.23 Cr | -0.36 Cr | 0.82 Cr | 1.24 Cr | — |
| Interest Expense | 0.23 Cr | 0.36 Cr | 0.08 Cr | 0.11 Cr | — |
| Normalized Income | 19.50 Cr | 16.78 Cr | 10.64 Cr | 8.11 Cr | — |
| Net Income From Continuing And Discontinued Operation | 19.50 Cr | 16.78 Cr | 12.58 Cr | 14.09 Cr | — |
| Total Expenses | 109.90 Cr | 102.59 Cr | 85.07 Cr | 100.97 Cr | — |
| Diluted NI Availto Com Stockholders | 19.50 Cr | 16.78 Cr | 12.58 Cr | 14.09 Cr | — |
| Net Income Common Stockholders | 19.50 Cr | 16.78 Cr | 12.58 Cr | 14.09 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 19.50 Cr | 16.78 Cr | 12.58 Cr | 14.09 Cr | — |
| Net Income Including Noncontrolling Interests | 19.50 Cr | 16.78 Cr | 12.58 Cr | 14.09 Cr | — |
| Net Income Continuous Operations | 19.50 Cr | 16.78 Cr | 12.58 Cr | 14.09 Cr | — |
| Tax Provision | 6.16 Cr | 3.91 Cr | 3.31 Cr | 5.47 Cr | — |
| Pretax Income | 25.67 Cr | 20.68 Cr | 15.89 Cr | 19.56 Cr | — |
| Other Non Operating Income Expenses | 23.35 Cr | 14.89 Cr | 2.88 Cr | 0.15 Cr | — |
| Special Income Charges | 0.00 | 0.00 | -0.60 Cr | -0.54 Cr | — |
| Net Non Operating Interest Income Expense | -0.23 Cr | -0.36 Cr | 0.82 Cr | 1.24 Cr | — |
| Interest Expense Non Operating | 0.23 Cr | 0.36 Cr | 0.08 Cr | 0.11 Cr | — |
| Operating Income | 2.55 Cr | 6.15 Cr | 7.34 Cr | 9.54 Cr | — |
| Operating Expense | 33.44 Cr | 27.98 Cr | 23.57 Cr | 24.88 Cr | — |
| Other Operating Expenses | 16.85 Cr | 12.74 Cr | 4.27 Cr | 5.45 Cr | — |
| Depreciation And Amortization In Income Statement | 2.20 Cr | 1.95 Cr | 1.33 Cr | 1.66 Cr | — |
| Depreciation Income Statement | 2.20 Cr | 1.95 Cr | 1.33 Cr | 1.66 Cr | — |
| Gross Profit | 35.99 Cr | 34.13 Cr | 30.91 Cr | 34.43 Cr | — |
| Cost Of Revenue | 76.47 Cr | 74.60 Cr | 61.50 Cr | 76.09 Cr | — |
| Total Revenue | 112.45 Cr | 108.74 Cr | 92.41 Cr | 110.51 Cr | — |
| Operating Revenue | 112.45 Cr | 108.74 Cr | 92.41 Cr | 110.51 Cr | — |
| Interest Income | — | 2.32 Cr | 1.04 Cr | 1.46 Cr | 0.65 Cr |
| Rent Expense Supplemental | — | 0.07 Cr | 0.06 Cr | 0.07 Cr | 0.06 Cr |
| Diluted Average Shares | — | 2.09 Cr | 2.10 Cr | 2.10 Cr | 2.10 Cr |
| Basic Average Shares | — | 2.09 Cr | 2.10 Cr | 2.10 Cr | 2.10 Cr |
| Diluted EPS | — | 8.01 | 5.88 | 6.70 | 3.45 |
| Basic EPS | — | 8.01 | 5.88 | 6.70 | 3.45 |
| Write Off | — | 0.41 Cr | 0.60 Cr | 0.54 Cr | 2.31 Cr |
| Total Other Finance Cost | — | 0.04 Cr | 0.14 Cr | 0.11 Cr | 0.05 Cr |
| Interest Income Non Operating | — | 2.32 Cr | 1.04 Cr | 1.46 Cr | 0.65 Cr |
| Selling General And Administration | — | 7.52 Cr | 6.26 Cr | 7.52 Cr | 6.69 Cr |
| Selling And Marketing Expense | — | 5.95 Cr | 5.16 Cr | 5.79 Cr | 4.49 Cr |
| General And Administrative Expense | — | 1.57 Cr | 1.10 Cr | 1.72 Cr | 2.20 Cr |
| Rent And Landing Fees | — | 0.07 Cr | 0.06 Cr | 0.07 Cr | 0.06 Cr |
| Amortization | — | — | — | — | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Alpa Laboratories Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.